Microchip Technology Inc. vs 22nd Century Group Inc — how do they compare? Microchip Technology Inc. trades at $82.66 (market cap $43.72B), while 22nd Century Group Inc trades at $4.25 (market cap $1.49M). The key difference: Microchip Technology Inc. is far larger — about 29342.3× 22nd Century Group Inc's market cap, and Microchip Technology Inc. pays a 2.26% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| MCHP | XXII | |
|---|---|---|
Market Cap | $43.72B | $1.49M |
Sector | Technology | Technology |
52-Week High | $102.97 | $1.07K |
52-Week Low | $49.02 | $3.90 |
Enterprise Value | $49.01B | -$6.74M |
Dividend Yield | 2.26% | — |
Signals from Pluang's Aura AI — not financial advice
MCHP trades at $80.64, down 0.4% on the day, with technical indicators signaling a bearish trend. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 expected at $0.70 EPS. Revenue declined to $4.40B in 2025, resulting in a net loss, but margins are projected to recover in 2026. Positive sentiment is driven by AI and aerospace demand, with 68% of analysts rating it a Buy.
Outlook is mixed: strong analyst consensus targets $113.33, but high P/E of 368 and recent net loss pose valuation risks. Key opportunities include AI data center growth and inventory recovery, while supply chain constraints and semiconductor cycle volatility remain headwinds. The stock offers upside if earnings rebound as forecasted.
XXII trades at $4.32, down 0.23% with bearish technical signals. The company shows negative profitability with -65.76% net income margin and -130.19% ROE, though valuation ratios appear low with P/S of 0.03. Recent corporate actions include a 20:1 reverse stock split in June 2026. The company is expanding VLN product distribution in key markets including California and New York, supported by positive FDA regulatory developments.
While analyst consensus is 75% buy-rated, fundamental challenges persist with consistent revenue declines and negative cash flow from operations. Investment opportunity lies in successful VLN brand expansion and regulatory approvals, but risks include ongoing losses, competitive tobacco market pressures, and execution uncertainty in scaling reduced-nicotine products.
Trailing returns across standard periods
Latest headlines on both assets
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →